Leucuţa S E, Vida-Simiti L, Căprioară M G, Făgărăşan E, Olinic N, Manasia M, Vlaicu R
Institute of Medicine and Pharmacy, Department of Pharmaceutical Technology and Biopharmaceutics, Cluj-Napoca, Romai.
Pharmazie. 1989 May;44(5):336-8.
The absolute and relative bioavailability of nifedipine (1) from different formulations administered as single oral doses in healthy volunteers was determined. Serum concentrations of 1 were measured by GC. The absolute bioavailability of 1 was 53% because of presystemic metabolism. The bioavailability of Adalat (Bayer) tablets, Nifedipina (Terapia) and Corinfar (VEB Arzneimittelwerk Dresden) sugar-coated tablets was 93%, 92% and 86% (respectively) as compared with Adalat capsules. The AUC were not significantly different. The Cmax and tmax values were different, indicating that the absorption of 1 showed differences in first-order rate constants of dissolution in the above mentioned order. Despite the differences among the formulations studied, each preparation may have its merits. In a multiple dose regimen of 20 mg 1 (Nifedipina, Terapia) t.i.d., minimal therapeutic drug levels were achieved and maintained during steady state, from the 1st d of treatment.
测定了健康志愿者单次口服不同制剂硝苯地平(1)的绝对生物利用度和相对生物利用度。通过气相色谱法测定1的血清浓度。由于首过代谢,1的绝对生物利用度为53%。与拜耳的心痛定胶囊相比,拜耳公司的心痛定片、Terapia公司的硝苯地平片和德累斯顿VEB制药厂的可力平糖衣片的生物利用度分别为93%、92%和86%。曲线下面积无显著差异。最大血药浓度(Cmax)和达峰时间(tmax)值不同,表明1的吸收在上述顺序的溶出一级速率常数上存在差异。尽管所研究的制剂之间存在差异,但每种制剂可能都有其优点。在20mg 1(Terapia公司的硝苯地平片)每日三次的多剂量给药方案中,从治疗第1天起,在稳态期间达到并维持了最低治疗药物水平。